Overview of Progress in the Epidemiology of Age-Related Macular Degeneration

REFERENCES

• Ferris F L, III. Senile macular degeneration: Review of epidemiologic features. Am J Epidemiol. 1983; 118(2)132–151
   PubMed Web of Science ®Google Scholar
• Leibowitz H M, Krueger D E, Maunder L R, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol. 1980; 24: 335–610, (Suppl)
   PubMedGoogle Scholar
• Klein B E, Klein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol. 1982; 100(4)571–573
   Google Scholar
• Hyman L G, Lilienfeld A M, Ferris F L, III, et al. Senile macular degeneration: A case-control study. Am J Epidemiol. 1983; 118(2)213–227
   PubMed Web of Science ®Google Scholar
• Delaney W V, Jr., Oates R P. Senile macular degeneration: A preliminary study. Ann Ophthalmol. 1982; 14(1)21–24
   Google Scholar
• Maltzman B A, Mulvihill M N, Greenbaum A. Senile macular degeneration and risk factors: A case-control study. Ann Ophthalmol. 1979; 11(8)1197–1201
   Google Scholar
• Klein R. Epidemiology. Age-Related Macular Degeneration, J W Berger, S L Fine, M G Maguire. Mosby, St. Louis 1999; 31–56
   Google Scholar
• Friedman D S, Katz J, Bressler N M, et al. Racial differences in the prevalence of age-related macular degeneration: The Baltimore Eye Survey. Ophthalmology. 1999; 106(6)1049–1055
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Linton K L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992; 99(6)933–943
   PubMed Web of Science ®Google Scholar
• Schachat A P, Hyman L, Leske M C, et al. Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol. 1995; 113(6)728–735
   PubMedGoogle Scholar
• Vingerling J R, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995; 102(2)205–210
   PubMed Web of Science ®Google Scholar
• Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995; 102(10)1450–1460
   PubMed Web of Science ®Google Scholar
• VanNewkirk M R, Weih L, McCarty C A, et al. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology. 2001; 108(5)960–967
   PubMed Web of Science ®Google Scholar
• Munoz B, Klein R, Rodriguez J, et al. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol. 2005; 123(11)1575–1580
   Google Scholar
• Varma R, Fraser-Bell S, Tan S, et al. Prevalence of age-related macular degeneration in Latinos: The Los Angeles Latino eye study. Ophthalmology. 2004; 111(7)1288–1297
   PubMed Web of Science ®Google Scholar
• Freeman E E, Munoz B, Bressler S B, et al. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: The Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005; 12(1)37–45
   PubMed Web of Science ®Google Scholar
• Delcourt C, Diaz J L, Ponton-Sanchez A, et al. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol. 1998; 116(8)1031–1035
   Google Scholar
• Klein R, Davis M D, Magli Y L, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991; 98(7)1128–1134
   PubMed Web of Science ®Google Scholar
• Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001; 108(4)697–704
   PubMed Web of Science ®Google Scholar
• Tomany S C, Wang J J, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents. Ophthalmology. 2004; 111(7)1280–1287
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Knudtson M D, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006; 113(3)373–380
   PubMed Web of Science ®Google Scholar
• Congdon N, O'Colmain B, Klaver C C, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122(4)477–485
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Lee K E, et al. The fifteen-year cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology 2007; 114: 253–262
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Lee K E, et al. Changes in visual acuity in a population over a 15-year period: The Beaver Dam Eye Study. Am J Ophthalmol. 2006; 142(4)539–549
   PubMed Web of Science ®Google Scholar
• Klein R. Epidemiology of age-related macular degeneration. Macular Degeneration: Science and Medicine in Practice, P L Penfold, J M Provis. Springer-Verlag, New York 2005; 79–121
   Google Scholar
• Haddad S, Chen C A, Santangelo S L, et al. The genetics of age-related macular degeneration: A review of progress to date. Surv Ophthalmol. 2006; 51(4)316–363
   PubMedGoogle Scholar
• Seddon J M, George S, Rosner B, et al. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered. 2006; 61(3)157–165
   PubMed Web of Science ®Google Scholar
• Schaumberg D A, Hankinson S E, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol. 2007; 125(1)55–62
   PubMedGoogle Scholar
• Deangelis M M, Ji F, Kim I K, et al. Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol. 2007; 125(1)49–54
   Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119(10)1417–1436
   PubMed Web of Science ®Google Scholar
• Gragoudas E S, Adamis A P, Cunningham E T, Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27)2805–2816
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Brown D M, Heier J S, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14)1419–1431
   PubMed Web of Science ®Google Scholar
• Bressler N M, Bressler S B, Congdon N G, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003; 121(11)1621–1624
   PubMed Web of Science ®Google Scholar